<unk> , sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth. Side effects of<unk>  include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2.<unk>  has a relatively short elimination half-life of 8hours and a time to peak of about 1 to 2hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action.<unk>  was approved for medical use in the United States in January 2022. It is expected to become available in May 2022. The medication is a schedule IV controlled substance in the United States.
Daridorexant
Seltorexant
Suvorexant
Veristrat
Bocasan
Toremifene
Icatibant
Fenproporex